LYSAKARE

This brand name is authorized in Austria, Croatia, Estonia, France, Hong Kong SAR China, Ireland, Italy, Japan, Lithuania, Poland, UK.

Active ingredients

The drug LYSAKARE contains a combination of these active pharmaceutical ingredients (APIs):

1	Arginine UNII F7LTH1E20Y - ARGININE HYDROCHLORIDE
	Arginine is an essential amino acid that is physiologically active in the L-form. It is commonly found as a component of total parenteral nutrition.
	Read more about Arginine
2	Lysine UNII JNJ23Q2COM - LYSINE HYDROCHLORIDE
	Read more about Lysine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LYSAKARE Solution for infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V03AF11		V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AF Detoxifying agents for antineoplastic treatment
Discover more medicines within V03AF11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1800032
FR	Base de données publique des médicaments	65395602
GB	Medicines & Healthcare Products Regulatory Agency	386102
HK	Department of Health Drug Office	66931
IT	Agenzia del Farmaco	048100010
JP	医薬品医療機器総合機構	3253416A1020
LT	Valstybinė vaistų kontrolės tarnyba	1088319
PL	Rejestru Produktów Leczniczych	100424790